跳至主要内容
临床试验/EUCTR2004-001910-15-IT
EUCTR2004-001910-15-IT进行中(未招募)不适用

RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTI-CENTRE, PHASE IIB/III STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF SLIT ADMINISTERED AS TABLETS ONCE DAILY TO PATIENTS SUFFERING FROM GRASSES POLLEN RHINOCONJUNCTIVITIS

STALLERGENES0 个研究点开始时间: 2005年3月3日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
STALLERGENES

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
STALLERGENES

相似试验

已完成
不适用
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder-F31F31
PER-070-06OVARTIS BIOSCIENSES PERU S.A.,
未知
不适用
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE IIB DOSE FINDING STUDY OF GLPG0634 ADMINISTERED FOR 24 WEEKS IN COMBINATION WITH METHOTREXATE TO SUBJECTS WITHMODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE AN INADEQUATE RESPONSE TO METHOTREXATE ALONE-M06M06
PER-057-13Galapagos N.V,
进行中(未招募)
1 期
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients with mild Alzheimer's Disease (STEADFAST)
EUCTR2016-002005-19-IEvTv THERAPEUTICS LLC800
进行中(未招募)
1 期
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients with mild Alzheimer's Disease (STEADFAST)MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINEMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10012268Term: Dementia (excl Alzheimer's type)System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012296Term: Dementia of the Alzheimer's type, with depressed moodSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012295Term: Dementia of the Alzheimer's type, with delusionsSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012294Term: Dementia of the Alzheimer's type, with deliriumSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10012293Term: Dementia of the Alzheimer's type, uncomplicatedSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10012292Term: Dementia of the Alzheimer's type NOSSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: LLTClassification code 10066571Term: Progression of Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2016-002005-19-GBvTv THERAPEUTICS LLC800
已完成
1 期
DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, MULTICENTRIC STUDY TO EVALUATE THE SECURITY AND EFFICACY OF 2 MG 3 TIMES PER DAY OF CILANSETRON FOR 12 WEEKS, FOLLOWED BY A RANDOMIZED 4-WEEK TREATMENT PERIOD IN SUBJECTS WITH IRRITABLE COLON SYNDROME WITH PREDOMINANCE DIARRHEAL.-K580 Irritable bowel syndrome with diarrhoeaIrritable bowel syndrome with diarrhoeaK580
PER-004-03SOLVAY PHARMACEUTICALS,